Does the media favor AGIO or LNTH?

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Lantheus. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 4 mentions for Lantheus. Agios Pharmaceuticals' average media sentiment score of 0.74 beat Lantheus' score of 0.65 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SYRE or AGIO?

In the previous week, Spyre Therapeutics and Spyre Therapeutics both had 7 articles in the media. Agios Pharmaceuticals' average media sentiment score of 0.74 beat Spyre Therapeutics' score of 0.26 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Agios Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor IMVT or AGIO?

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Immunovant. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.64 beat Agios Pharmaceuticals' score of 0.74 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Agios Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AGIO or PTGX?

In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 6 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.23 beat Agios Pharmaceuticals' score of 0.74 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AGIO or TGTX?

In the previous week, TG Therapeutics had 6 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 13 mentions for TG Therapeutics and 7 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.74 beat TG Therapeutics' score of 0.69 indicating that Agios Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Agios Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TG Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Agios Pharmaceuticals (AGIO) Competitors

$28.82 -0.06 (-0.19%)

As of 12:47 PM Eastern

Compare

AGIO vs. LNTH, SYRE, IMVT, PTGX, and TGTX

Should you buy Agios Pharmaceuticals stock or one of its competitors? MarketBeat compares Agios Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Agios Pharmaceuticals include Lantheus (LNTH), Spyre Therapeutics (SYRE), Immunovant (IMVT), Protagonist Therapeutics (PTGX), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry.

How does Agios Pharmaceuticals compare to Lantheus?

Agios Pharmaceuticals (NASDAQ:AGIO) and Lantheus (NASDAQ:LNTH) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, risk, institutional ownership, profitability, valuation, earnings, media sentiment and analyst recommendations.

Agios Pharmaceuticals presently has a consensus price target of $40.89, indicating a potential upside of 41.85%. Lantheus has a consensus price target of $101.86, indicating a potential downside of 0.34%. Given Agios Pharmaceuticals' higher probable upside, equities research analysts plainly believe Agios Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Lantheus. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 4 mentions for Lantheus. Agios Pharmaceuticals' average media sentiment score of 0.74 beat Lantheus' score of 0.65 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.1% of Lantheus shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by company insiders. Comparatively, 1.7% of Lantheus shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lantheus has a net margin of 18.05% compared to Agios Pharmaceuticals' net margin of -639.84%. Lantheus' return on equity of 29.32% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
Lantheus	18.05%	29.32%	15.00%

Lantheus has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	31.73	-$412.78M	-$7.25	N/A
Lantheus	$1.55B	4.30	$233.56M	$4.15	24.63

Agios Pharmaceuticals has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market. Comparatively, Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market.

Summary

Lantheus beats Agios Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

In the previous week, Spyre Therapeutics and Spyre Therapeutics both had 7 articles in the media. Agios Pharmaceuticals' average media sentiment score of 0.74 beat Spyre Therapeutics' score of 0.26 indicating that Agios Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Agios Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Spyre Therapeutics has a beta of 3.05, meaning that its stock price is 205% more volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

80.4% of Spyre Therapeutics shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Spyre Therapeutics has higher earnings, but lower revenue than Agios Pharmaceuticals. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$2.08	N/A
Agios Pharmaceuticals	$54.03M	31.73	-$412.78M	-$7.25	N/A

Spyre Therapeutics has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Spyre Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

Spyre Therapeutics currently has a consensus price target of $91.33, indicating a potential upside of 15.89%. Agios Pharmaceuticals has a consensus price target of $40.89, indicating a potential upside of 41.85%. Given Agios Pharmaceuticals' higher probable upside, analysts plainly believe Agios Pharmaceuticals is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

Spyre Therapeutics beats Agios Pharmaceuticals on 10 of the 15 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Agios Pharmaceuticals (NASDAQ:AGIO) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

In the previous week, Agios Pharmaceuticals had 3 more articles in the media than Immunovant. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 4 mentions for Immunovant. Immunovant's average media sentiment score of 1.64 beat Agios Pharmaceuticals' score of 0.74 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Agios Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agios Pharmaceuticals has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Agios Pharmaceuticals	$54.03M	31.73	-$412.78M	-$7.25	N/A

Immunovant currently has a consensus price target of $37.33, indicating a potential upside of 15.21%. Agios Pharmaceuticals has a consensus price target of $40.89, indicating a potential upside of 41.85%. Given Agios Pharmaceuticals' higher possible upside, analysts clearly believe Agios Pharmaceuticals is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Agios Pharmaceuticals has a beta of 0.59, indicating that its stock price is 41% less volatile than the broader market.

Immunovant has a net margin of 0.00% compared to Agios Pharmaceuticals' net margin of -639.84%. Agios Pharmaceuticals' return on equity of -34.11% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%

47.1% of Immunovant shares are held by institutional investors. 1.8% of Immunovant shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Agios Pharmaceuticals beats Immunovant on 8 of the 13 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to Protagonist Therapeutics?

Agios Pharmaceuticals (NASDAQ:AGIO) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, media sentiment, institutional ownership, risk, valuation, profitability and dividends.

Protagonist Therapeutics has higher revenue and earnings than Agios Pharmaceuticals. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Agios Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	31.73	-$412.78M	-$7.25	N/A
Protagonist Therapeutics	$74.06M	94.13	-$130.15M	-$1.81	N/A

Protagonist Therapeutics has a net margin of -154.88% compared to Agios Pharmaceuticals' net margin of -639.84%. Protagonist Therapeutics' return on equity of -17.76% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 5.2% of Protagonist Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

In the previous week, Agios Pharmaceuticals had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 7 mentions for Agios Pharmaceuticals and 6 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.23 beat Agios Pharmaceuticals' score of 0.74 indicating that Protagonist Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Protagonist Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Agios Pharmaceuticals has a beta of 0.59, meaning that its share price is 41% less volatile than the broader market. Comparatively, Protagonist Therapeutics has a beta of 1.85, meaning that its share price is 85% more volatile than the broader market.

Agios Pharmaceuticals presently has a consensus price target of $40.89, indicating a potential upside of 41.85%. Protagonist Therapeutics has a consensus price target of $115.21, indicating a potential upside of 6.29%. Given Agios Pharmaceuticals' higher possible upside, equities analysts plainly believe Agios Pharmaceuticals is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88

Summary

Protagonist Therapeutics beats Agios Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Agios Pharmaceuticals compare to TG Therapeutics?

Agios Pharmaceuticals (NASDAQ:AGIO) and TG Therapeutics (NASDAQ:TGTX) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, earnings, analyst recommendations, institutional ownership, dividends, profitability and risk.

58.6% of TG Therapeutics shares are owned by institutional investors. 5.4% of Agios Pharmaceuticals shares are owned by insiders. Comparatively, 10.6% of TG Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Agios Pharmaceuticals has a beta of 0.59, suggesting that its share price is 41% less volatile than the broader market. Comparatively, TG Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the broader market.

TG Therapeutics has a net margin of 65.95% compared to Agios Pharmaceuticals' net margin of -639.84%. TG Therapeutics' return on equity of 88.73% beat Agios Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Agios Pharmaceuticals	-639.84%	-34.11%	-31.66%
TG Therapeutics	65.95%	88.73%	43.44%

In the previous week, TG Therapeutics had 6 more articles in the media than Agios Pharmaceuticals. MarketBeat recorded 13 mentions for TG Therapeutics and 7 mentions for Agios Pharmaceuticals. Agios Pharmaceuticals' average media sentiment score of 0.74 beat TG Therapeutics' score of 0.69 indicating that Agios Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Agios Pharmaceuticals	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TG Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

TG Therapeutics has higher revenue and earnings than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Agios Pharmaceuticals	$54.03M	31.73	-$412.78M	-$7.25	N/A
TG Therapeutics	$700.35M	10.53	$447.18M	$2.86	16.84

Agios Pharmaceuticals presently has a consensus price target of $40.89, indicating a potential upside of 41.85%. TG Therapeutics has a consensus price target of $52.50, indicating a potential upside of 8.98%. Given Agios Pharmaceuticals' higher probable upside, equities research analysts clearly believe Agios Pharmaceuticals is more favorable than TG Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Agios Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
TG Therapeutics	0 Sell rating(s)	3 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.71

Summary

TG Therapeutics beats Agios Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

Get Agios Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AGIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AGIO vs. The Competition

Export

Metric	Agios Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.71B	$3.35B	$6.49B	$11.73B
Dividend Yield	N/A	2.33%	2.67%	5.61%
P/E Ratio	-3.96	19.61	24.65	23.79
Price / Sales	31.73	174.19	476.12	85.79
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	1.41	8.10	10.45	6.74
Net Income	-$412.78M	$23.89M	$3.56B	$337.26M
7 Day Performance	-0.07%	-3.36%	-2.43%	-1.85%
1 Month Performance	2.98%	-2.11%	0.23%	0.94%
1 Year Performance	-16.23%	39.32%	21.35%	24.84%

Agios Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AGIO Agios Pharmaceuticals	3.3175 of 5 stars	$28.83 -0.2%	$40.89 +41.9%	-16.3%	$1.71B	$54.03M	N/A	390	Analyst Forecast
LNTH Lantheus	3.1901 of 5 stars	$100.01 -1.0%	$101.86 +1.8%	+24.6%	$6.57B	$1.54B	24.10	1,193
SYRE Spyre Therapeutics	2.1108 of 5 stars	$72.00 -2.2%	$91.33 +26.9%	+304.5%	$6.40B	$890K	N/A	73
IMVT Immunovant	3.3206 of 5 stars	$30.80 -1.0%	$37.33 +21.2%	+86.3%	$6.39B	N/A	N/A	120	Positive News
PTGX Protagonist Therapeutics	1.6311 of 5 stars	$98.03 +0.7%	$115.21 +17.5%	+87.6%	$6.26B	$46.02M	N/A	120	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AGIO) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. LNTH, SYRE, IMVT, PTGX, and TGTX

How does Agios Pharmaceuticals compare to Lantheus?

Summary

How does Agios Pharmaceuticals compare to Spyre Therapeutics?

Summary

How does Agios Pharmaceuticals compare to Immunovant?

Summary

How does Agios Pharmaceuticals compare to Protagonist Therapeutics?

Summary

How does Agios Pharmaceuticals compare to TG Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Agios Pharmaceuticals (AGIO) Competitors

AGIO vs. LNTH, SYRE, IMVT, PTGX, and TGTX

How does Agios Pharmaceuticals compare to Lantheus?

Do analysts rate AGIO or LNTH?

Does the media favor AGIO or LNTH?

Do insiders and institutionals believe in AGIO or LNTH?

Is AGIO or LNTH more profitable?

Which has preferable earnings and valuation, AGIO or LNTH?

Which has more risk and volatility, AGIO or LNTH?

Summary

How does Agios Pharmaceuticals compare to Spyre Therapeutics?

Does the media favor SYRE or AGIO?

Which has more volatility and risk, SYRE or AGIO?

Do insiders & institutionals believe in SYRE or AGIO?

Which has stronger valuation and earnings, SYRE or AGIO?

Is SYRE or AGIO more profitable?

Do analysts recommend SYRE or AGIO?

Summary

How does Agios Pharmaceuticals compare to Immunovant?

Does the media favor IMVT or AGIO?

Which has stronger earnings & valuation, IMVT or AGIO?

Do analysts rate IMVT or AGIO?

Which has more risk and volatility, IMVT or AGIO?

Is IMVT or AGIO more profitable?

Do institutionals and insiders believe in IMVT or AGIO?

Summary

How does Agios Pharmaceuticals compare to Protagonist Therapeutics?

Which has preferable earnings & valuation, AGIO or PTGX?

Is AGIO or PTGX more profitable?

Do insiders & institutionals believe in AGIO or PTGX?

Does the media prefer AGIO or PTGX?

Which has more risk & volatility, AGIO or PTGX?

Do analysts recommend AGIO or PTGX?

Summary

How does Agios Pharmaceuticals compare to TG Therapeutics?

Do insiders and institutionals believe in AGIO or TGTX?

Which has more volatility & risk, AGIO or TGTX?

Is AGIO or TGTX more profitable?

Does the media refer more to AGIO or TGTX?

Which has better valuation & earnings, AGIO or TGTX?

Do analysts recommend AGIO or TGTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AGIO vs. The Competition

Agios Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools